The inventors have developed a methodology that has been robustly validated (~800 patients) to accurately and reliably measure Ox-LDL, AGE-LDL and other modified LDLs in both free and bound/immune-complex forms that are directly correlated with potential development of severe atherosclerotic disease, higher morbidity and mortality. These findings have significant utility in predicting cardiovascular disease and complications in patients well before the onset of clinically detectable disease. This method of collection, separation and detection of a range of modified LDLs and LDL immune complexes is more consistent, reliable and robust than other currently available methods.
Clinical atherosclerosis affects more than 25 million Americans. That number does not reflect the substantial portion of the population that has asymptomatic, subclinical atherosclerosis. According to the NHLBI’s MESA study, subclinical atherosclerotic subjects with coronary artery calcification are four to ten times more likely to experience a coronary event than subjects with no calcification. Current methods for detecting subclinical atherosclerosis, chest CT or neck ultrasound are costly. Early identification of high risk patients could target the patient population that requires additional screening and aggressive intervention to minimize irreversible damage such as nephropathy, heart attack and blindness. Having a reliable, inexpensive method of screening would allow for appropriate adjustments to therapy both early on and over time.
More consistent and reliable than other current methods of LDL detection; robust validation already performed
Key Words: Atherosclerosis, LDL, subclinical atherosclerosis, cardiovascular disease, diabetes, coronary artery disease
Publications: Klein, Richard L., et al. "LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses." Journal of diabetes and its complications 25.2 (2011): 73-82.
Inventors: Maria Lopes-Virella and Gabriel Virella
Patent Status: US Patent 12/885,020
MUSC-FRD Technology ID: P0923